Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
In those with type 2 diabetes (T2D), insulin production is reduced or impaired, leading to higher blood sugar levels. Therefore good control of blood sugar is vital to avoid long term complications, such as damage to the blood vessels. Controlling the amount of carbohydrate (reducing starch and sugar whilst increasing fibre intake) consumed can help manage T2D, by lowering post meal blood glucose levels. It is recommended that the daily diet consist of 50% carbohydrate, however there is little evidence to support recommendations of carbohydrate intake in those with T2D, despite starch making up a substantial part of the daily diet. Additionally, there is misinformation amongst the general public in respect of carbohydrates in terms of what the evidence-base actually shows in terms of the effects on blood glucose. General advice is to replace “white” carbohydrates such as bread and pasta, with “wholegrain” alternatives, however there is resistance in consuming these alternatives, and in reality they contain similar amounts of starch/fibre to “white” carbohydrates, labelling a food “wholegrain” can lead to perception that it is a high fibre product which is confusing. Our comparison of “white bread” versus “wholewheat” bread, demonstrated there was no difference in blood glucose response between the two because there was no difference in digestible starch. Therefore when addressing dietary carbohydrate, the focus must be on the “starch” component of the diet. A health claim was recently approved by the European Food Safety Authority in 2011 due to the weight of evidence, in that replacing only 14% rapidly digestible starch with resistant starch (a type of fibre), can reduce post meal blood glucose levels, however this same effect has not been tested in those with T2D. The aim of this study is to observe the effect of replacing a proportion of starch (not the type of food) with resistant starch in the diet, on blood glucose levels in patients with T2D. Study objectives include: recruiting 20 patients with T2D from local population in Surrey, who meet our inclusion criteria, and primarily recruited through GP surgeries, via local primary care research network. Eligible participants will screened to determine suitability, and if they wish to take part, consent will be obtained. Participants will they undertake a dietary intervention study to examine the effects of 2 x 4 day diets that differ only in their composition of starch, in a randomised order. Non-invasive subcutaneous continuous glucose monitoring will be undertaken during each 4 day period.

Who can participate?
We are inviting people who have been living with T2D for more than 6 months, aged 18-70 to take part, and taking part will involve:

What does the study involve?
Screening: This visit will last approximately 90 minutes, during which time you will complete questionnaires relating to your health and current medication. Height and weight will be recorded, and a fasting blood sample will be collected to assess if you are healthy enough to take part, and allow a baseline HbA1c for you. Your diet will be discussed with a dietician, to determine your normal diet, including likes and dislikes from the food options that are available for the trial.
Study days: You will need to attend the Clinical Investigation Unit (CIU) at the University of Surrey on two separate occasions to be fitted with a glucose monitor to continuously measure your glucose levels over a period of 5 days. The continuous glucose monitors (CGM) are small remote devices, the size of a two pence piece, that sit flush with the skin in a discreet location, once fitted.
The two periods of monitoring consist of the following:
i) A CIU visit, followed by 4 days of dietary intake “diet 1” as per the diet plan provided (control diet), with 50% total energy as digestible starch.
ii) A CIU visit, followed by 4 days of dietary intake “diet 2” as per the diet plan provided (resistant starch diet), with 20% digestible starch replaced with resistant starch.
There will be at least a week between the 2 test diets. Only the 4 day intervention will you be asked to eat only meals on the diet sheet provided to you. You will calibrate the CGM you are wearing, using a lancet device to measure your blood glucose prior to eating and recording this figure. Removal of the CGM will take 5 mins at the CIU on day 6. You are are free to withdraw at any time, including your data prior to the final download on of CGM day 4.

What are the possible benefits and risks of participating?
The benefits of participating include: increased understanding of the role of food in blood glucose management. A report of the CGM data collected during the study can be used form links between dietary habits and blood glucose, which could be considered more efficacious than a single blood sample. Studies like this, can help future dietary guidelines for diabetes management, which may be different from that recommended as part of normal healthy eating. We do not anticipate there to be any risks to taking part as the foods provided come from commercial sources. The CGM are routinely used in clinical practice for the monitoring of free living out-patients. They are deemed safe and non-intrusive. Participants are free to bathe and shower as normal, or go swimming. As the study involves modification to your diet and visits to the University of Surrey campus, participants will be recompensed £200 plus reasonable travel expenses on completion of all study visits.

Where is the study run from?
The study will be run solely from the: University of Surrey, Guildford, FHMS Clinical Investigation Unit (CIU) (UK).

When is the study starting and how long is it expected to run for?
Recruitment is expected to start on 1st July 2019, and will continue for 12 months, during which time the study will continue, ending when data has been collected, and it is anticipated that analysis will begin July 2020.

Who is funding the study?
The project is being funded by Diabetes UK []

Who is the main contact?
Principal Investigator: Dr Denise Robertson, Reader in Nutritional Physiology, Faculty of Health and Medical sciences, Leggett Building, Manor Road Campus, Guildford, GU2 9NR;

Trial website

Contact information



Primary contact

Dr Sineaid Collins


Contact details

Faculty of Health and Medical Sciences
Leggett Building
Manor Park Campus
United Kingdom
+44(0)1483 686993

Additional identifiers

EudraCT number

Nil known number

Nil known

Protocol/serial number


Study information

Scientific title

Carbohydrate in the diet. A starch exchange model for managing glycaemia in type 2 diabetes.


Study hypothesis

Replacing some of the starch in the diet with resistant starch, will reduce blood glucose levels in those with type 2 diabetes.

Ethics approval

Approved 24/08/2018, NHS HRA South West - Cornwall & Plymouth Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT; 0207 104 8059;, ref: REC 18/SW/0204 IRAS number 240102.

Study design

Single centre single blinded randomised controlled crossover trial

Primary study design


Secondary study design

Randomised cross over trial

Trial setting


Trial type

Quality of life

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet


Type 2 diabetes


Participants will consume either diet 1 or diet 2 for 4 consecutive days. Control diet is “diet 1” and will include 50% carbohydrate comprising standard starch versions of bread, pasta and snack crackers. A one week break will then follow prior to commencement of the alternate treatment period in which the alternate diet is consumed for 4 days consecutively. “Diet 2” will have 20% of the digestible starch being replaced with resistant starch, a type of fibre. This will include high fibre versions (using resistant starch) of pasta, bread and crackers. Both "diet 1" and "diet 2" will be the same in nutrient composition, except for starch/fibre content.
As part of the screening process, the potential participant’s diet will be discussed with a dietitian, and “diet 1” and “diet 2” in order to personalise the diet to ensure it is within daily recommendations of fat, protein and carbohydrate and energy intake, based on height and weight.
Participants will be fitted with a glucose monitor to continuously measure glucose levels.

Intervention type



Drug names

Primary outcome measure

Postprandial glucose (MAGE) excursion resulting from consumption of both diets. The MAGE calculation will be made by measuring the arithmetic mean of the difference between consecutive peaks and nadirs. Blood glucose will be measured continuously, however time points of interest are: 8.15am-9.00am (post breakfast), 10.30am-11.15am (post snacks), 12pm-12.45pm (post lunch), 6.00pm-6.45pm (post dinner).

Secondary outcome measures

1. Peak postprandial glucose excursion after meals
2. The time to peak postprandial glucose excursion
3. Mean blood glucose
4. The standard deviation of blood glucose
5. 24-hour glucose area under the curve (AUC).
Blood glucose will be measured continuously, however time points of interest are: 8.15am-9.00am (post breakfast), 10.30am-11.15am (post snacks), 12pm-12.45pm (post lunch), 6.00pm-6.45pm (post dinner).

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Patients with a diagnosis of type 2 diabetes > 6 months,
2. Males and females,
3. 18-70yrs,
4. Access to a kitchen,
5. Ability to understand English (to provide informed consent).

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Use of insulin and GLP-1 analogues,
2. History of gastroperesis or gastric surgery,
3. Coeliac disease/wheat intolerance,
4. Irritable bowel syndrome,
5. HbA1c >75 mmol/mol,
6. Pregnancy/breast-feeding,
7. Excess alcohol intake,
8. Glucose-lowering drug dosage adjustment within the previous month.

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Clinical Investigation Unit (CIU) University of Surrey
University of Surrey
United Kingdom

Sponsor information


University of Surrey

Sponsor details

388 Stag Hill
United Kingdom
+441483 300800

Sponsor type




Funder type


Funder name

Diabetes UK

Alternative name(s)

Funding Body Type

private sector organisation

Funding Body Subtype

Other non-profit organizations


United Kingdom

Results and Publications

Publication and dissemination plan

A lay summary of the data from the whole study will be provided to participants.
Publication of the data in peer reviewed journals
Presentation of results at conferences and to patient voluntary groups.

IPD sharing statement:
All data generated or analysed during this study will be included in the subsequent results publication

Intention to publish date


Participant level data


Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

29/09/2020: Recruitment to this study is no longer paused. 17/08/2020: The following changes were made to the trial record: 1. The recruitment end date was changed from 01/07/2020 to 01/12/2020. 2. The overall trial end date was changed from 01/07/2020 to 01/02/2021. 3. The intention to publish date was changed from 01/03/2021 to 01/09/2021. 20/04/2020: Due to current public health guidance, recruitment for this study has been paused as of 23/03/2020. 05/04/2019: Internal review.